125 related articles for article (PubMed ID: 21790306)
1. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
Hoff CM; Lassen P; Eriksen JG; Hansen HS; Specht L; Overgaard M; Grau C; Johansen J; Bentzen J; Andersen L; Evensen JF; Overgaard J
Acta Oncol; 2011 Oct; 50(7):1006-14. PubMed ID: 21790306
[TBL] [Abstract][Full Text] [Related]
2. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study.
Hoff CM; Hansen HS; Overgaard M; Grau C; Johansen J; Bentzen J; Overgaard J
Radiother Oncol; 2011 Jan; 98(1):28-33. PubMed ID: 20970213
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
4. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
[TBL] [Abstract][Full Text] [Related]
6. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for head and neck tumors.
Reichel O; Panzer M; Wimmer C; Dühmke E; Kastenbauer E; Suckfüll M
Eur Arch Otorhinolaryngol; 2003 May; 260(5):248-53. PubMed ID: 12750913
[TBL] [Abstract][Full Text] [Related]
8. Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome.
Bhide SA; Ahmed M; Rengarajan V; Powell C; Miah A; Newbold K; Nutting CM; Harrington KJ
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):391-8. PubMed ID: 18692326
[TBL] [Abstract][Full Text] [Related]
9. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
Machtay M; Pajak TF; Suntharalingam M; Shenouda G; Hershock D; Stripp DC; Cmelak AJ; Schulsinger A; Fu KK;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1008-17. PubMed ID: 17716826
[TBL] [Abstract][Full Text] [Related]
11. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma.
Tanvetyanon T; Choudhury AM
Cancer; 2006 Apr; 106(7):1554-9. PubMed ID: 16518817
[TBL] [Abstract][Full Text] [Related]
12. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
[TBL] [Abstract][Full Text] [Related]
13. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
14. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
[TBL] [Abstract][Full Text] [Related]
15. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
16. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma--a prospective study.
Hoff CM; Grau C; Overgaard J
Radiother Oncol; 2012 Apr; 103(1):38-44. PubMed ID: 22385797
[TBL] [Abstract][Full Text] [Related]
17. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03.
Rabinovitch R; Grant B; Berkey BA; Raben D; Ang KK; Fu KK; Cooper JS;
Head Neck; 2006 Apr; 28(4):287-96. PubMed ID: 16287132
[TBL] [Abstract][Full Text] [Related]
18. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
[TBL] [Abstract][Full Text] [Related]
19. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial.
Haffty BG; Hurley R; Peters LJ
Cancer J Sci Am; 1999; 5(6):341-7. PubMed ID: 10606475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
